Acumen Pharmaceuticals will host a virtual investor day on Sept. 16 to outline its Alzheimer’s strategy and the potential of AβO-directed therapies. Investors will get updates on the ALTITUDE-AD phase 2 study, sabirnetug’s mechanism and pipeline progress.
published
Acumen Pharmaceuticals will host a virtual investor day on Sept. 16 to outline its Alzheimer’s strategy and the potential of AβO-directed therapies. Investors will get updates on the ALTITUDE-AD phase 2 study, sabirnetug’s mechanism and pipeline progress.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.